title: Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy.
abstract: We previously encountered a patient with epilepsy who exhibited rapid elimination of sustained-release valproic acid (VPA) administered at the dose of 2.8 g/d as a sodium salt. The purpose of this study was to clarify the relationship between the VPA elimination rate and the proportion of the dose excreted in urine as its glucuronide conjugate (VPA-G) in epileptic patients. Twenty-four-hour urine was collected from four epileptic patients who had taken VPA orally (age: 16-39 y, weight: 50-63 kg, dose: 1.0-2.8 g/d). VPA and its metabolites were detected by gas chromatography-mass spectrometry. The amounts of VPA, VPA-G, 3-keto VPA, and 3-OH VPA excreted in the 24-h urine were 1.8-13.2, 178-2158, 125-320, and 8.6-18.7 mg (converted into VPA), respectively, and 0.2-0.5, 20.5-88.7, 5.8-18.7, and 0.6-1.0% of the dose administered, respectively. The dose of VPA correlated well with the proportion of the dose excreted in urine as VPA-G in each patient, and the patients administered a high dose excreted a large amount of VPA-G in the urine. Thus, differences in the VPA-G production rate may be one of the major variable factors affecting the elimination of administered VPA. We also present a dynamic model of VPA in the kidney which may explain the VPA elimination phenomena in humans on the basis of the data obtained here regarding the concentrations of VPA and its metabolites in plasma and their urinary excretion levels.
authors.affiliation: Department of Pharmacy, Yamaguchi University Hospital, Ube, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Hirozane
authors.forename: H
authors.initials: H
authors.lastname: Kimoto
authors.forename: T
authors.initials: T
authors.lastname: Hayashi
authors.forename: T
authors.initials: T
authors.lastname: Akiyama
authors.forename: H
authors.initials: H
authors.lastname: Katayama
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Yoshitomi
authors.forename: A
authors.initials: A
authors.lastname: Kamiya
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D004827:Epilepsy / Q000378:metabolism*; D005965:Glucuronates / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D014635:Valproic Acid / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D000927:Anticonvulsants; D005965:Glucuronates; D014635:Valproic Acid